Baillie Gifford European Growth Ord (BGEU.L)
| Previous close | 92.60 |
| Open | 0.00 |
| Bid | 93.80 x N/A |
| Ask | 93.90 x N/A |
| Day's range | 92.50 - 94.20 |
| 52-week range | 75.38 - 111.47 |
| Volume | |
| Avg. volume | 546,287 |
| Market cap | 333.167M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 13.46 |
| EPS (TTM) | N/A |
| Earnings date | 27 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GuruFocus.comBaillie Gifford's Strategic Moves in Q2 2024: A Closer Look at NVIDIA Corp's Impact
Insight into Baillie Gifford (Trades, Portfolio)'s Latest 13F Filings and Portfolio Adjustments
GuruFocus.comBaillie Gifford Reduces Stake in Ginkgo Bioworks Holdings Inc
On June 1, 2024, Baillie Gifford (Trades, Portfolio), a prominent investment management firm, executed a significant transaction involving the shares of Ginkgo Bioworks Holdings Inc (NYSE:DNA). Baillie Gifford (Trades, Portfolio), established over a century ago, is renowned for its commitment to long-term, bottom-up investment approaches, focusing on fundamental analysis and proprietary research.
GuruFocus.comBaillie Gifford's Strategic Reduction in Alnylam Pharmaceuticals Holdings
On June 1, 2024, Baillie Gifford (Trades, Portfolio) executed a significant transaction involving the sale of 590,921 shares of Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), marking a notable reduction in their investment. The transaction was carried out at a price of $148.43 per share, impacting Baillie Gifford (Trades, Portfolio)'s portfolio by -0.07%.
